SCHEMBL3767565

SCHEMBL3767565

CC(C)(C)OC(=O)N1CCN(c2nc(-c3ccc(F)cc3)cs2)CC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.74
MAPK1 P28482 6/20 0.74
SMN1; SMN2 Q16637 6/20 0.74
LMNA P02545 5/20 0.74
HTT P42858 3/20 0.74
L3MBTL1 Q9Y468 4/20 0.64
ALDH1A1 P00352 5/20 0.61
TSHR P16473 2/20 0.59
NPSR1 Q6W5P4 1/20 0.59
CYP1A2 P05177 2/20 0.59
CYP2C19 P33261 2/20 0.59
CYP3A4 P08684 1/20 0.58
GAA P10253 1/20 0.58
CYP2C9 P11712 1/20 0.58
RAB9A P51151 3/20 0.56
NPC1 O15118 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
AR P10275 2/20 0.56
FAAH O00519 1/20 0.56
ENPP2 Q13822 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29157428 0.89 MAPT (0.74) MAPTMAPK1SMN1; SMN2LMNAHTT
SCHEMBL13208949 0.89 MAPT (0.58) MAPTMAPK1SMN1; SMN2LMNAHTT
SCHEMBL3765754 0.89 RAB9A (0.66) MAPTMAPK1SMN1; SMN2LMNAHTT
SCHEMBL17541711 0.88 MAPT (0.67) MAPTMAPK1SMN1; SMN2LMNAHTT
SCHEMBL1473079 0.88 MAPT (0.58) MAPTMAPK1SMN1; SMN2LMNAHTT
SCHEMBL3764614 0.87 FAAH (0.58) MAPTMAPK1SMN1; SMN2LMNAHTT
SCHEMBL4584400 0.86 MAPT (0.56) MAPTMAPK1SMN1; SMN2LMNAHTT
SCHEMBL3761098 0.85 FAAH (0.58) MAPTMAPK1SMN1; SMN2LMNAHTT
SCHEMBL27315644 0.85 LMNA (0.59) MAPTMAPK1SMN1; SMN2LMNAHTT
SCHEMBL3776873 0.83 SMN1; SMN2 (0.58) MAPTMAPK1SMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
CN-101103007-A Amide compound TAKEDA PHARMACEUTICAL (JP) 2008-01-09 CN disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 MAPT 3805/4885MAPK1 2636/4885SMN1; SMN2 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.